Scarica l'app Stockscreener
2.03
0.23%
-0.0046
Pre-mercato:
2.20
0.17
+8.37%
Precedente Chiudi:
$2.0346
Aprire:
$2.0821
Volume 24 ore:
3,493
Relative Volume:
0.20
Capitalizzazione di mercato:
$187.13M
Reddito:
$47.04M
Utile/perdita netta:
$-63.98M
Rapporto P/E:
-2.5174
EPS:
-0.8064
Flusso di cassa netto:
$-34.39M
1 W Prestazione:
+5.73%
1M Prestazione:
+14.36%
6M Prestazione:
+14.69%
1 anno Prestazione:
-2.87%
Intervallo 1D:
$2.03
$2.0821
Intervallo di 1 settimana:
$1.87
$2.10
Portata 52W:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Nome
Innate Pharma Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IPHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.03 | 187.52M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Iniziato | Goldman | Neutral |
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World
Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India
Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
AZN Stock Price and Chart — LSE:AZN - TradingView
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat
Innate Pharma Adr Azioni (IPHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):